Benitec Biopharma (BNTC) Stock Price, News & Analysis

Company Overview

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. The hepatitis B program is advancing through preclinical studies to demonstrate potent and durable suppression of viral replication. In ocular disease, the company is exploring local delivery approaches to address wet age-related macular degeneration and other retinal disorders with RNAi-based constructs.

Founded and headquartered in Australia, Benitec maintains research operations in both Melbourne and San Diego, California. Its international footprint supports collaboration with academic centers and contract development organizations to accelerate preclinical evaluation and future clinical trials. The company holds a portfolio of intellectual property covering its ddRNAi technology and related gene-silencing applications.

Led by a management team with experience in gene therapy, molecular biology and drug development, Benitec Biopharma is focused on translating its platform into clinical-stage assets. The company continues to explore partnerships and licensing opportunities to broaden the scope of its gene-silencing pipeline and advance novel treatments toward regulatory approval.

Key Stats

• Today's Range: $12.04 to $12.70
• 50-Day Range: $10.06 to $14.08
• 52-Week Range: $9.85 to $17.15
• Volume: 37,122 shs
• Average Volume: 147,226 shs
• Market Capitalization: $432.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.67
• Consensus Rating: Moderate Buy

Benitec Biopharma Stock Analysis - MarketRank™

Benitec Biopharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 674th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Benitec Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Benitec Biopharma has a consensus price target of $27.67, representing about 130.5% upside from its current price of $12.01.

Amount of Analyst Coverage

Benitec Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.05) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Benitec Biopharma is -10.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Benitec Biopharma is -10.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Benitec Biopharma has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.93% of the float of Benitec Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Benitec Biopharma has a short interest ratio ("days to cover") of 21.61, which indicates bearish sentiment.

Change versus previous month

Short interest in Benitec Biopharma has recently decreased by 1.72%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Benitec Biopharma does not currently pay a dividend.

Dividend Growth

Benitec Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.05

News Sentiment

Benitec Biopharma has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Benitec Biopharma this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for BNTC on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Benitec Biopharma is held by insiders.

Percentage Held by Institutions

52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BNTC Stock Analysis - Frequently Asked Questions

How have BNTC shares performed this year?

Benitec Biopharma's stock was trading at $13.47 at the start of the year. Since then, BNTC stock has decreased by 10.9% and is now trading at $12.0050.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Limited (NASDAQ:BNTC) issued its quarterly earnings results on Thursday, February, 12th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03.

When did Benitec Biopharma's stock split?

Benitec Biopharma's stock reverse split before market open on Wednesday, July 26th 2023.The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's top institutional investors include Simplify Asset Management Inc. (1.64%) and Bank of New York Mellon Corp (0.13%).
View institutional ownership trends.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 2/12/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTC
• CIK: 1808898
• Web: www.benitec.com
• Phone: 510-780-0819
• Fax: 61 (0)3 9966-9923
• Employees: 20
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Benitec Biopharma: $27.67
• High Price Target: $32.00
• Low Price Target: $22.00
• Potential Upside/Downside: +121.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.92%
• Return on Assets: -37.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 67.69
• Quick Ratio: 67.69

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 5,356.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.71 per share
• Price / Book: 3.36

Miscellaneous

• Outstanding Shares: 34,350,000
• Free Float: 32,705,000
• Market Cap: $428.52 million
• Optionable: No Data
• Beta: 0.28